Nls Pharmaceutics Ag Stock Cash And Equivalents
| NLSPW Stock | USD 0.01 0.0001 0.91% |
NLS Pharmaceutics AG fundamentals help investors to digest information that contributes to NLS Pharmaceutics' financial success or failures. It also enables traders to predict the movement of NLS Stock. The fundamental analysis module provides a way to measure NLS Pharmaceutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NLS Pharmaceutics stock.
NLS | Cash And Equivalents |
NLS Pharmaceutics AG Company Cash And Equivalents Analysis
NLS Pharmaceutics' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current NLS Pharmaceutics Cash And Equivalents | 145.4 K |
Most of NLS Pharmaceutics' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NLS Pharmaceutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
NLS Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for NLS Pharmaceutics is extremely important. It helps to project a fair market value of NLS Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since NLS Pharmaceutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of NLS Pharmaceutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of NLS Pharmaceutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, NLS Pharmaceutics AG has 145.4 K in Cash And Equivalents. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The cash and equivalents for all United States stocks is notably lower than that of the firm.
NLS Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NLS Pharmaceutics' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NLS Pharmaceutics could also be used in its relative valuation, which is a method of valuing NLS Pharmaceutics by comparing valuation metrics of similar companies.NLS Pharmaceutics is currently under evaluation in cash and equivalents category among its peers.
NLS Pharmaceutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of NLS Pharmaceutics from analyzing NLS Pharmaceutics' financial statements. These drivers represent accounts that assess NLS Pharmaceutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of NLS Pharmaceutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.3B | 557.1M | 654.8M | 1.0B | 897.9M | 1.1B | |
| Enterprise Value | 1.3B | 559.1M | 649.4M | 1.0B | 898.6M | 1.1B |
NLS Fundamentals
| Return On Asset | -2.28 | ||||
| Number Of Shares Shorted | 18.05 K | ||||
| EBITDA | (11.8 M) | ||||
| Net Income | (12.17 M) | ||||
| Cash And Equivalents | 145.4 K | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 1.63 M | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (9.40) X | ||||
| Cash Flow From Operations | (9.68 M) | ||||
| Beta | -0.52 | ||||
| Market Capitalization | 37.77 M | ||||
| Total Asset | 1.85 M | ||||
| Retained Earnings | (70.37 M) | ||||
| Working Capital | (6.1 M) | ||||
| Net Asset | 1.85 M |
About NLS Pharmaceutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NLS Pharmaceutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NLS Pharmaceutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NLS Pharmaceutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for NLS Stock Analysis
When running NLS Pharmaceutics' price analysis, check to measure NLS Pharmaceutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NLS Pharmaceutics is operating at the current time. Most of NLS Pharmaceutics' value examination focuses on studying past and present price action to predict the probability of NLS Pharmaceutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NLS Pharmaceutics' price. Additionally, you may evaluate how the addition of NLS Pharmaceutics to your portfolios can decrease your overall portfolio volatility.